Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Autolus Therapeutics Ltd

AUTL
Current price
4.19 USD -0.09 USD (-2.10%)
Last closed 4.28 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 727 723 392 USD
Yield for 12 month +30.12 %
Week
Month
Year
AUTL
21.11.2021 - 28.11.2021

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The MediaWorks, London, United Kingdom, W12 7FP

Analytics

WallStreet Target Price

8.52 USD

P/E ratio

Dividend Yield

Current Year

+6 194 000 USD

Last Year

+2 330 000 USD

Current Quarter

+406 000 USD

Last Quarter

Current Year

+6 194 000 USD

Last Year

+2 330 000 USD

Current Quarter

+24 000 USD

Last Quarter

Key Figures AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -159 684 000 USD
Operating Margin TTM -2223.7 %
PE Ratio
Return On Assets TTM -27.2 %
PEG Ratio
Return On Equity TTM -69.88 %
Wall Street Target Price 8.52 USD
Revenue TTM 7 486 000 USD
Book Value 1.32 USD
Revenue Per Share TTM 0.055 USD
Dividend Share
Quarterly Revenue Growth YOY 678.3 %
Dividend Yield
Gross Profit TTM -130 860 000 USD
Earnings Share -1.19 USD
Diluted Eps TTM -1.19 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AUTL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 95.0675
Price Sales TTM 97.2113
Enterprise Value EBITDA -3.4813
Price Book MRQ 4.0385

Financials AUTL

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AUTL

For 52 weeks

1.6 USD 4.83 USD
50 Day MA 3.14 USD
Shares Short Prior Month 1 466 674
200 Day MA 2.65 USD
Short Ratio 4.82
Shares Short 1 483 746
Short Percent 1.75 %